Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Afatinib and Talc Pleurodesis for EGFR+ NSCLC
NCT03827070Phase 1Unknown
- Sponsor
- Center Trials & Treatment Europe
- Start
- Mar 2019
- Primary completion
- Feb 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Center Trials & Treatment Europe. Primary endpoint: The effectiveness of the procedure of dry pleurodesis through a thoracoscope at 90 days. Status: unknown.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03827070.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03827070.